121135-53-3|Scriptene|[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl [(2S,5R)-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl hydrogen phosphate|-范德生物科技公司

Scriptene

NMR下载 COA and HPLC MSDS下载
names：
[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl [(2S,5R)-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl hydrogen phosphate
CAS号：
121135-53-3
MDL Number：
MF(分子式)： C20H24N9O9P MW(分子量)： 565.4398
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl [(2S,5R)-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl hydrogen phosphate
英文别名	Scriptene
CAS号	121135-53-3
SMILES	O=P(OC[C@H]1O[C@@H](N2C=NC3=C2N=CNC3=O)CC1)(OC[C@H]4O[C@@H](N(C(N5)=O)C=C(C)C5=O)C[C@@H]4N=[N+]=[N-])O
Inchi	InChI=1S/C20H24N9O9P/c1-10-5-28(20(32)25-18(10)30)15-4-12(26-27-21)13(38-15)7-36-39(33,34)35-6-11-2-3-14(37-11)29-9-24-16-17(29)22-8-23-19(16)31/h5,8-9,11-15H,2-4,6-7H2,1H3,(H,33,34)(H,22,23,31)(H,25,30,32)/t11-,12-,13+,14+,15+/m0/s1
InchiKey	XURFYCWNUGWGDL-VQJWOFKYSA-N
分子式 Formula	C20H24N9O9P
分子量 Molecular Weight	565.4398
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Scriptene(CAS:121135-53-3):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Scriptene is an antiviral heterodimer composed of one molecule of 3'-azido-3'-deoxythymidine (AZT) and one molecule of 2',3'-dideoxyinosine (ddI) linked through their 5' positions by a phosphate bond
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Walker DM, Kajon AE, Torres SM, Carter MM, McCash CL, Swenberg JA, Upton PB, Hardy AW, Olivero OA, Shearer GM, Poirier MC, Walker VE. WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication. Environ Mol Mutagen. 2009 Jul;50(6):460-72. doi: 10.1002/em.20482. PubMed PMID: 19334055; PubMed Central PMCID: PMC3197270.

[2]Pan-Zhou XR, Cretton-Scott E, Zhou XJ, Xie MY, Rahmani R, Schinazi RF, Duchin K, Sommadossi JP. Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes. Antimicrob Agents Chemother. 1997 Nov;41(11):2502-10. PubMed PMID: 9371357; PubMed Central PMCID: PMC164152.

[3] Zhou XJ, Squires K, Pan-Zhou XR, Bernhard S, Agrofoglio L, Kirk M, Duchin KL, Sommadossi JP. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. J Clin Pharmacol. 1997 Mar;37(3):201-13. PubMed PMID: 9089422.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开